Background: Symptomatic intracranial hemorrhage is a rare complication of laser interstitial thermal therapy (LITT). Objectives: To present a unique case of delayed symptomatic intracranial hemorrhage occurring after a LITT procedure for epilepsy in a high-volume center (68 LITT procedures for pediatric epilepsy have been performed). Methods: An 18-year-old male with epilepsy underwent LITT to an area of heterotopia near the right lateral ventricle. He did well initially and was discharged home on postoperative day 1 but returned on postoperative day 9 with headache and left hemiparesis. He was found to have intraparenchymal and intraventricular hemorrhage in the region of the LITT catheter tract. Results: CT angiography on admission revealed a small vascular abnormality near the focus of hemorrhage suspicious for pseudoaneurysm, although conventional angiography was negative. The patient declined neurologically and underwent craniotomy and hemorrhage evacuation. He eventually convalesced and was discharged to inpatient rehabilitation with persistent left hemiparesis. He has been seizure free since the intervention but remains on antiepileptic drugs. Conclusions: Evidence from the literature suggests that the pathophysiology of symptomatic hemorrhage after LITT may be related to vascular injury and pseudoaneurysm formation from LITT catheter placement and/or thermal injury from the ablation itself.

Keywords:
Epilepsy, Intracranial hemorrhage, Laser ablation, Pseudoaneurysm, Stereotactic techniques
1.
Bown SG: Phototherapy in tumors. World J Surg 1983;7:700-709.
2.
Medvid R, Ruiz A, Komotar RJ, Jagid JR, Ivan ME, Quencer RM, et al: Current applications of MRI-guided laser interstitial thermal therapy in the treatment of brain neoplasms and epilepsy: a radiologic and neurosurgical overview. Am J Neuroradiol 2015;36:1998-2006.
3.
Willie JT, Laxpati NG, Drane DL, Gowda A, Appin C, Hao C, et al: Real-time magnetic resonance-guided stereotactic laser amygdalohippocampotomy for mesial temporal lobe epilepsy. Neurosurgery 2014;74:569-584.
4.
Sloan AE, Ahluwalia MS, Valerio-Pascua J, Manjila S, Torchia MG, Jones SE, et al: Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma: clinical article. J Neurosurg 2013;118:1202-1219.
5.
Hawasli AH, Kim AH, Dunn GP, Tran DD, Leuthardt EC: Stereotactic laser ablation of high-grade gliomas. Neurosurg Focus 2014;37:E1.
6.
Curry DJ, Gowda A, McNichols RJ, Wilfong AA: MR-guided stereotactic laser ablation of epileptogenic foci in children. Epilepsy Behav 2012;24:408-414.
7.
Schwarzmaier HJ, Eickmeyer F, von Tempelhoff W, Fiedler VU, Niehoff H, Ulrich SD, et al: MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: preliminary results in 16 patients. Eur J Radiol 2006;59:208-215.
8.
Mohammadi AM, Hawasli AH, Rodriguez A, Schroeder JL, Laxton AW, Elson P, et al: The role of laser interstitial thermal therapy in enhancing progression-free survival of difficult-to-access high-grade gliomas: a multicenter study. Cancer Med 2014;3:971-979.
9.
Jethwa PR, Barrese JC, Gowda A, Shetty A, Danish SF: Magnetic resonance thermometry-guided laser-induced thermal therapy for intracranial neoplasms: initial experience. Neurosurgery 2012;71(suppl 1):133-144.
10.
Buckley R, Estronza-Ojeda S, Ojemann JG: Laser ablation in pediatric epilepsy. Neurosurg Clin N Am 2016;27:69-78.
11.
Field M, Witham TF, Flickinger JC, Kondziolka D, Lunsford LD: Comprehensive assessment of hemorrhage risks and outcomes after stereotactic brain biopsy. J Neurosurg 2001;94:545-551.
12.
Sansur C, Frysinger RC, Pouratian N, Fu K-M, Bittl M, Oskouian RJ, et al: Incidence of symptomatic hemorrhage after stereotactic electrode placement. J Neurosurg 2007;107:998-1003.
13.
Beric A, Kelly PJ, Rezai A, Sterio D, Mogilner A, Zonenshayn M, et al: Complications of deep brain stimulation surgery. Stereotact Funct Neurosurg 2001;77:73-78.
14.
Binder DK, Rau GM, Starr PA: Risk factors for hemorrhage during microelectrode-guided deep brain stimulator implantation for movement disorders. Neurosurgery 2005;56:722-728.
15.
Favre J, Taha JM, Burchiel KJ: An analysis of the respective risks of hematoma formation in 361 consecutive morphological and functional stereotactic procedures. Neurosurgery 2002;50:48-56.
16.
Gorgulho A, De Salles A a F, Frighetto L, Behnke E: Incidence of hemorrhage associated with electrophysiological studies performed using macroelectrodes and microelectrodes in functional neurosurgery. J Neurosurg 2005;102:888-896.
17.
Lyons KE, Wilkinson SB, Overman J, Pahwa R: Surgical and hardware complications of subthalamic stimulation: a series of 160 procedures. Neurology 2004;63:612-616.
18.
Bernays RL, Kollias SS, Khan N, Brandner S, Meier S, Yonekawa Y: Histological yield, complications, and technological considerations in 114 consecutive frameless stereotactic biopsy procedures aided by open intraoperative magnetic resonance imaging. J Neurosurg 2002;97:354-362.
19.
Jackson RJ, Fuller GN, Abi-Said D, Lang FF, Gokaslan ZL, Shi WM, et al: Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol 2001;3:193-200.
20.
Kongkham PN, Knifed E, Tamber MS, Bernstein M: Complications in 622 cases of frame-based stereotactic biopsy, a decreasing procedure. Can J Neurol Sci 2008;35:79-84.
21.
Kulkarni A V, Guha A, Lozano A, Bernstein M: Incidence of silent hemorrhage and delayed deterioration after stereotactic brain biopsy. J Neurosurg 1998;89:31-35.
22.
Sawin PD, Hitchon PW, Follett KA, Torner JC: Computed imaging-assisted stereotactic brain biopsy: a risk analysis of 225 consecutive cases. Surg Neurol 1998;49:640-649.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.